arrow
H

Howard Colman

clinical neurosciences center
H指数:71
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

实体瘤内的多细胞免疫生态型可预测免疫检查点抑制剂的实际治疗效果

2025-11-130
OAAI
UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA

更新后的III期STELLAR试验结果:依氟鸟氨酸改善2021年WHO分级3级IDH突变型星形细胞瘤患者的总生存期和盲态独立中央审查确定的无进展生存期

2025-11-010
OAAI
Multivariate survival risk stratification in GBMs lacking necrosis and microvascular proliferation

胶质母细胞瘤中缺乏坏死和微血管增生的多变量生存风险分层

2025-11-010
OAAI
PNOC025: A phase 1 study assessing the safety and tolerability of magrolimab in children and adults with recurrent or progressive malignant brain tumors

PNOC025:一项评估magrolimab在复发性或进展性恶性脑肿瘤儿童和成人患者中的安全性与耐受性的1期研究

2025-11-010
PRE
Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma

帕米帕利(Pamiparib)联合放疗和/或替莫唑胺(Temozolomide)治疗初治或复发性/难治性胶质母细胞瘤成人的Ib/II期研究

2025-09-290
OAAI
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

作者更正: 溶瘤DNX-2401病毒疗法联合pembrolizumab治疗复发性胶质母细胞瘤: 1/2期试验

2025-07-210
OA
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy

关键免疫T细胞群在恶性肿瘤中的差异浸润,其免疫原性潜力和对免疫疗法的反应可能性各不相同

CELLS
IF5.2
2024-12-030
OAAI
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
2024-11-220
OAAI
EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

PAXALISIB在新诊断和复发胶质母细胞瘤的GBM敏捷3期注册平台试验中的评估

2024-11-110
PRE
PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
2024-11-110
PRE
GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
2024-10-171
PRE